- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00860535
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
A Multicenter Phase Ib Trial to Determine Whether a Gene Expression Signature Changes in Response to Treatment With Bcr-Abl Inhibitors in Patients With Blast Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant must have a histologically or cytopathologically confirmed blast phase Ph+ CML or Ph+ ALL.
- Participant is 18 years of age on the day of signing informed consent
- Participant must have performance status 0-3 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
Participant has at least 30 percent blasts in peripheral blood; or at least 30 percent lymphoblasts in peripheral blood or bone marrow
- For Part II:
- Participant has progressed while taking imatinib or is unable to tolerate imatinib, being defined as discontinuing imatinib treatment as a result of nonhematologic toxic effects of any grade
- If female, participant is either post-menopausal, free from menses for >2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from heterosexual activity throughout the study, starting with Visit 1
- Female participants of childbearing potential must have a negative serum or urine pregnancy test (beta hCG) at screening
- If male, participant is surgically sterilized, agrees to use an adequate method of contraception, or agrees to abstain from heterosexual activity for the duration of the study
- Participant or the patrticipant's legal representative has voluntarily agreed to participate by giving written informed consent
- Participant must be available for periodic blood sampling, study related assessments, and management at the treating institution for the duration of the study
Exclusion Criteria:
- Participant is currently participating in or has participated in a study with an investigational compound or device within 30 days or 5 half-lives, whichever is longer, of the start of treatment
- Participant has known human immunodeficiency virus (HIV) infection or HIV-related malignancy
- Participant is a female who is pregnant or breastfeeding, or is expecting to conceive within the projected duration of the study
- Participant has a known allergy or hypersensitivity to imatinib, dasatinib or nilotinib
- Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate
- Participant has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- There is any concern by the investigator regarding the safe participation of the participant in the study or for any other reason, the investigator considers the participant inappropriate for participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ph+ CML or Ph+ ALL
GFS biomarker evaluation
|
Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a ~3.5 month period. Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day [qd]), dasatinib (recommended dose 70 mg twice a day [bid]), or nilotinib (recommended dose 400 mg bid). Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Growth Factor Signature (GFS) Variability at Baseline
Time Frame: Screening to Day 1 Predose
|
The GFS was measured by microarray analysis using the entire 101 gene signature. The GFS is quantified as the change in gene expression between two separate samples collected from the same patient. The signature has 101 genes in two oppositely regulated arms, which are pre-specified. The expression of genes in the UP arm goes up with increasing pathway activity, and the expression of genes in the DOWN arm goes down with increasing pathway activity. The GFS variability was represented by the GFS change between two baseline samples (Mean GFS Fold Ratio [Screening to Day 1 Predose]). |
Screening to Day 1 Predose
|
Growth Factor Signature (GFS) Change From Baseline Measured by Time Weighted Average (TWA) for Days 1 to 22
Time Frame: Baseline to 22 Days After Initiation of Therapy
|
The GFS was measured by microarray analysis using the entire 101 gene signature. The TWA is the area under the curve (AUC) divided by the time interval (for this study it was the AUC of gene-expression divided by Days 1 to 22). Participants with blast phase Ph+ CML or Ph+ ALL were measured for change in the GFS post-treatment when treated with imatinib, dasatinib, or nilotinib, using Microarray. Change was represented as the GFS Fold Ratio of TWA for Days 1 to 22 to Baseline. |
Baseline to 22 Days After Initiation of Therapy
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Neoplastic Processes
- Cell Transformation, Neoplastic
- Carcinogenesis
- Chromosome Aberrations
- Translocation, Genetic
- Leukemia
- Leukemia, Myeloid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Blast Crisis
- Philadelphia Chromosome
Other Study ID Numbers
- 0000-098
- 2009_558
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)United States
-
Children's Oncology GroupPfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...Active, not recruitingAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CMLUnited States
-
Novartis PharmaceuticalsTerminatedCML | Philadelphia Chromosome Positive (Ph+) | Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough LevelsUnited States
-
Novartis PharmaceuticalsCompletedPhiladelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
-
UNC Lineberger Comprehensive Cancer CenterCompletedChronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous LeukemiaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...United States
-
EDDC (Experimental Drug Development Centre), A*STAR...Chiltern International Inc.WithdrawnPh+ Acute Lymphoblastic Leukemia (Ph+ALL) | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) | Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)United States, Singapore
-
Incyte Biosciences UKCompletedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous LeukemiaUnited Kingdom, Ireland
-
Bristol-Myers SquibbCompletedLeukemia, Lymphoblastic, Acute, Philadelphia-positive | Leukemia, Myeloid, Chronic-phaseUnited States
-
Il-Yang Pharm. Co., Ltd.RecruitingChronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML, Refractory | CML - Philadelphia ChromosomeTurkey, Korea, Republic of, Russian Federation, Ukraine
Clinical Trials on Comparator: Biomarker evaluation
-
The Cleveland ClinicCompletedCardiovascular DiseasesUnited States
-
University Hospital, BordeauxCelgeneRecruitingMultiple SclerosisFrance
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)UnknownBreast Cancer | brca1 Mutation Carrier | brca2 Mutation CarrierUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
IRCCS Eugenio MedeaCompletedIntellectual Disability | Autism Spectrum Disorder | Attention Deficit Hyperactivity DisorderItaly
-
University Hospital, BordeauxRoche Pharma AGRecruitingMultiple Sclerosis, Primary ProgressiveFrance
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated
-
University Hospital, BordeauxRecruitingMultiple SclerosisFrance
-
University Hospital, CaenRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Motoric Cognitive Risk SyndromeFrance